Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2011 on request of the sponsor.
On 11 April 2005, orphan designation (EU/3/05/271) was granted by the European Commission to OneWorld Health, United Kingdom, for paromomycin sulfate for the treatment of visceral leishmaniasis.
The sponsorship was transferred to Sestria Ltd, United Kingdom, in November 2009.
Treatment of visceral leishmaniasis
|Orphan designation status||
|EU designation number||
|Date of designation||
88 High Street North
Bedfordshire LU7 0EW
Telephone: +44 7794 265 473
Telefax: +44 1525 240 504
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: